| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Purity: ≥98%
(-)-Quinpirole HCl [(-)-LY 171555] is a highly potent psychoactive drug and research chemical which acts as a high affinity and selective D₂ and D₃ receptor agonist. In scientific research, it is employed. In mice given quinpirole, there has been an increase in sniffing and mobility. In both in vitro and in vivo experiments, it is the most often utilized D2 agonist.
| Targets |
Dopamine D2/D3 receptor
|
|---|---|
| ln Vitro |
Although DA content is left brain biased in all groups, with saline controls showing a larger asymmetry than all drug-treated groups, Side and Group do not significantly interact. When examining each side independently, it becomes clear that chronic quinpirole treatment causes DA levels in the left brain structure to gradually drop, with the QQ rats showing a notable difference from the saline controls. Conversely, acute Quinpirole only causes a significant (increased) change in right cortical DA levels. Across groups, DOPAC levels are also found to be left brain biased. Nevertheless, no noteworthy Group or interaction effects are discovered. When compared to the QS group or saline controls, rats given acute quinpirole exhibit a specific increase in DA content and decrease in turnover ratio. When compared to the acute quinpirole group, the DOPAC levels of sensitized (QQ) rats are higher. All three of the DA function measures in the striatum also showed significant group differences (DA, F3,33=6.27, P=0.0020; F3,33=7.98, P=0.0004; turnover ratio, F3,33=16.85, P<0.0001), as well as differences in DA function. In comparison to all other groups, the acute quinpirole rats exhibit a significant decrease in both DOPAC and turnover ratio. The turnover ratio increased in both chronic quinpirole groups compared to both chronic saline groups, while DOPAC levels in QQ rats are significantly higher than in any other group[1].
|
| ln Vivo |
There was a left-brain bias in DA content between groups, and although this asymmetry was greater in the saline control group than in all drug-treated groups, there was no significant interaction between side and group. When considering each side individually, it can be seen that in left brain structures, DA levels gradually decrease with long-term quinpirole treatment, with significant differences between QQ rats and saline controls. In contrast, acute quinpirole only significantly altered (increased) right cortical DA levels. It was found that there was also a left-brain bias in DOPAC levels between groups. However, no significant group or interaction effects were found. Rats receiving acute quinpirole showed a selective increase in DA content and a decrease in turnover rate relative to the saline control or QS groups. However, DOPAC levels were increased in sensitized (QQ) rats compared with the acute quinpirole group. In the striatum, all three measures of DA function also differed significantly between groups (DA, F3,33=6.27, P=0.0020; DOPAC, F3,33=7.98, P=0.0004; turnover rate, F3,33=16.85, P <0.0001). In acute quinpirole rats, DOPAC and turnover rates were significantly reduced relative to all other groups. In QQ rats, DOPAC levels were significantly higher than all other groups, while in terms of turnover rate, both chronic quinpirole groups increased compared with the two chronic saline groups [1].
|
| Animal Protocol |
Rat: After giving injections of either saline or Quinpirole (Hydrochloride) (0.5 mg/kg, s.c., n = 18/condition) to 36 male Long-Evans rats every day for 12 days, the rats are promptly placed in Omnitech activity monitors (60×60×40 cm) for a 90-minute period. n=9/group) of rats in each chronic condition were given saline and half quinpirole on the last test day. Thus, the four groups stood for sensitized Quinpirole (drug) (QQ), acute Quinpirole (SQ), sensitized Quinpirole (no drug) (QS), and saline controls (SS). Thirty minutes following the last injection, every rat is taken out of the activity monitors and brought to a nearby room where it is promptly beheaded. Since acute quinpirole inhibits activity at this time, and chronic quinpirole is linked to marked hyperlocomotion at 30 minutes, this time point is selected to disentangle the behavioral effects of quinpirole between groups[1].
|
| References |
| Molecular Formula |
C13H22CLN3
|
|---|---|
| Molecular Weight |
255.78688
|
| Exact Mass |
255.15
|
| Elemental Analysis |
C, 61.04; H, 8.67; Cl, 13.86; N, 16.43
|
| CAS # |
85798-08-9
|
| Related CAS # |
rel-Quinpirole dihydrochloride; 73625-62-4
|
| Appearance |
Solid powder
|
| SMILES |
CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3.Cl
|
| InChi Key |
HJHVRVJTYPKTHX-HTMVYDOJSA-N
|
| InChi Code |
InChI=1S/C13H21N3.ClH/c1-2-5-16-6-3-4-10-7-12-11(8-13(10)16)9-14-15-12;/h9-10,13H,2-8H2,1H3,(H,14,15);1H/t10-,13-;/m1./s1
|
| Chemical Name |
(4aR,8aR)-5-propyl-1,4,4a,6,7,8,8a,9-octahydropyrazolo[3,4-g]quinoline;hydrochloride
|
| Synonyms |
LY-171555; LY 171555; LY171555; (-)Quinpirole hydrochloride; (-)-Quinpirole HCl; (-)Quinpirole HCl; (-) Quinpirole HCl
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ~50 mg/mL (~195.5 mM)
DMSO: ~27.8 mg/mL (~108.6 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.13 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.13 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (390.95 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9095 mL | 19.5473 mL | 39.0946 mL | |
| 5 mM | 0.7819 mL | 3.9095 mL | 7.8189 mL | |
| 10 mM | 0.3909 mL | 1.9547 mL | 3.9095 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA